Cargando…

Comprehensive analysis of prognosis‐related methylated sites in breast carcinoma

BACKGROUND: Breast carcinoma has become a nonnegligible public health problem in China with its increasing incidence and mortality in woman. As a early event regulating tumorigenesis and development, DNA methylation became one of the focuses of current carcinoma researches on potential diagnostic an...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jia, Li, Xinzheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196449/
https://www.ncbi.nlm.nih.gov/pubmed/32037691
http://dx.doi.org/10.1002/mgg3.1161
_version_ 1783528727045472256
author Li, Jia
Li, Xinzheng
author_facet Li, Jia
Li, Xinzheng
author_sort Li, Jia
collection PubMed
description BACKGROUND: Breast carcinoma has become a nonnegligible public health problem in China with its increasing incidence and mortality in woman. As a early event regulating tumorigenesis and development, DNA methylation became one of the focuses of current carcinoma researches on potential diagnostic and therapeutic targets. METHODS: In this study, we comprehensively analyzed the gene expression data and DNA methylation data of breast carcinoma and adjacent normal tissues samples in the Gene Expression Omnibus database. Influences of tumor stage, adjuvant therapy, hormone therapy, and chemotherapy on CpG methylation level were explored by linear regression analysis. Correlations between methylation and gene expression levels were determined by spearman rank correlation analysis. Log‐rank test was applied for determining significance of associations between CpG sites methylation level and breast cancer patients' Kaplan–Meier survival. RESULTS: A total of 229 CpG sites were found to be significantly associated with tumor stage or treatment, and eight of which were potential markers that affect the survival of breast carcinoma and negatively correlated with their genes' expression levels. CONCLUSIONS: We reported eight CpG sites as potential breast cancer prognosis signatures through comprehensively analyzed gene expression and DNA methylation datasets, and excluding influences of tumor stage and treatment. This should be helpful for breast cancer early diagnosis and treatment.
format Online
Article
Text
id pubmed-7196449
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-71964492020-05-04 Comprehensive analysis of prognosis‐related methylated sites in breast carcinoma Li, Jia Li, Xinzheng Mol Genet Genomic Med Original Articles BACKGROUND: Breast carcinoma has become a nonnegligible public health problem in China with its increasing incidence and mortality in woman. As a early event regulating tumorigenesis and development, DNA methylation became one of the focuses of current carcinoma researches on potential diagnostic and therapeutic targets. METHODS: In this study, we comprehensively analyzed the gene expression data and DNA methylation data of breast carcinoma and adjacent normal tissues samples in the Gene Expression Omnibus database. Influences of tumor stage, adjuvant therapy, hormone therapy, and chemotherapy on CpG methylation level were explored by linear regression analysis. Correlations between methylation and gene expression levels were determined by spearman rank correlation analysis. Log‐rank test was applied for determining significance of associations between CpG sites methylation level and breast cancer patients' Kaplan–Meier survival. RESULTS: A total of 229 CpG sites were found to be significantly associated with tumor stage or treatment, and eight of which were potential markers that affect the survival of breast carcinoma and negatively correlated with their genes' expression levels. CONCLUSIONS: We reported eight CpG sites as potential breast cancer prognosis signatures through comprehensively analyzed gene expression and DNA methylation datasets, and excluding influences of tumor stage and treatment. This should be helpful for breast cancer early diagnosis and treatment. John Wiley and Sons Inc. 2020-02-10 /pmc/articles/PMC7196449/ /pubmed/32037691 http://dx.doi.org/10.1002/mgg3.1161 Text en © 2020 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Li, Jia
Li, Xinzheng
Comprehensive analysis of prognosis‐related methylated sites in breast carcinoma
title Comprehensive analysis of prognosis‐related methylated sites in breast carcinoma
title_full Comprehensive analysis of prognosis‐related methylated sites in breast carcinoma
title_fullStr Comprehensive analysis of prognosis‐related methylated sites in breast carcinoma
title_full_unstemmed Comprehensive analysis of prognosis‐related methylated sites in breast carcinoma
title_short Comprehensive analysis of prognosis‐related methylated sites in breast carcinoma
title_sort comprehensive analysis of prognosis‐related methylated sites in breast carcinoma
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196449/
https://www.ncbi.nlm.nih.gov/pubmed/32037691
http://dx.doi.org/10.1002/mgg3.1161
work_keys_str_mv AT lijia comprehensiveanalysisofprognosisrelatedmethylatedsitesinbreastcarcinoma
AT lixinzheng comprehensiveanalysisofprognosisrelatedmethylatedsitesinbreastcarcinoma